Quantcast
Last updated on April 16, 2014 at 12:22 EDT

Latest Symphony Stories

2014-01-13 08:33:42

Product Information Management and Master Data Management help leading nationwide wholesaler integrate its operations NEW YORK, Jan. 13, 2014 /PRNewswire/ -- NRF Big Show - Symphony EYC, a global leader in delivering ROI for retailers, manufacturers, and wholesalers using customer insights to drive execution, today announced that Grand Rapid, MI-based SpartanNash Company, one of the nation's largest grocery distributors, has selected the Symphony EYC G.O.L.D. Master Data Management (MDM)...

2013-10-03 23:36:15

Long Islander Chris Pati, known locally as a musical genius since the age of 5, has created a way to bring global awareness to new music which is fast becoming the worldwide hub of independent and unsigned music and musicians. (PRWEB) October 03, 2013 Long Islander Chris Pati, known locally as a musical genius since the age of 5, has created a way to bring global awareness to new music which is fast becoming the worldwide hub of independent and unsigned music and musicians. Pati’s...

2013-09-09 16:23:45

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, Calif. and AMSTERDAM, Sept. 9, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines confirmed that Agendia's MammaPrint(®) tests, the leading product in Agendia's Symphony suite of breast cancer tests, significantly augment prognostic and predictive information in making key cancer...

2013-08-27 08:26:32

'High Risk' Patients with Unusual Hormone Receptors May Be Undertreated IRVINE, Calif. and AMSTERDAM, Aug. 27, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset of breast cancer patients whose standard biomarker tests may incorrectly classify patients as "low risk" and benefitting from endocrine therapy. A study published this month in Breast Cancer Research and Treatment* concluded that this subset of...

2013-06-03 12:27:55

Veteran Diagnostics and Biotech Executive to Lead Global Commercialization IRVINE, Calif. and AMSTERDAM, June 3, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer. In this newly created position, Mr. Schineller will lead Agendia's global commercialization activities as it delivers technologies to translate personalized diagnostics into actionable, patient-centered solutions for...

2013-05-31 12:24:08

IRVINE, Calif., May 31, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall...

2013-05-23 16:26:03

Genomic Testing Information for Breast Cancer Patients Now Available on New Website and Facebook Page IRVINE, Calif., May 23, 2013 /PRNewswire/ -- More than half of women diagnosed with early stage breast cancer may not benefit from chemotherapy and still have excellent outcomes. To educate women, Agendia, Inc. has announced the launch of one of the largest sources of online consumer information about breast cancer genomic tests. The new website and interactive Facebook page provide...

2013-05-02 12:29:02

Revenues Continue to Ramp in 2013 IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint test analyzes 70 key genes and accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy. Case volume grew by more than...

2013-01-25 12:25:19

IRVINE, Calif. and AMSTERDAM, Jan. 25, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the addition of Dr. Neil M. Barth as its Chief Medical Officer. In this role, Dr. Barth will translate complex laboratory science and personalized medicine diagnostics into actionable, patient centered solutions for clinicians. Dr. Barth is a highly skilled physician with 35 years of collective experience with innovative care delivery and genomic biomarker...

2012-11-27 12:29:35

IRVINE, Calif. and AMSTERDAM, Nov. 27, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types. The gene signature, discovered in collaboration with scientists from the Netherlands Cancer...